Cancer biomarkers

Molecular Oncology

Volumn 6, Issue 2, 2012, Pages 140-146

  Henry, N Lynn ^a   Hayes, Daniel F ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Medicinal Chemistry and Pharmacology   (United States)

Author keywords

Biomarker; Cancer; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTROGEN RECEPTOR; LACTATE DEHYDROGENASE; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DIFFERENTIAL DIAGNOSIS; EFFECT SIZE; FAMILY HISTORY; GENE EXPRESSION; GENE MUTATION; GENETIC SCREENING; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MANDATORY REPORTING; METHODOLOGY; NEOPLASM; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; STOMACH CANCER; TREATMENT RESPONSE; VALIDITY;

EID: 84860443642     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.01.010     Document Type: Review

References (42)

1. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., McAllister P.K., Morton R.F., Schilsky R.L. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27:2091-2096.
2. Allred D.C. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist 2008, 13:1134-1136.
3. Baggerly K.A., Morris J.S., Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20:777-785.
4. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
5. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., Moher D., Rennie D., de Vet H.C., Lijmer J.G. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann. Intern. Med. 2003, 138:W1-12.
6. Burstein H.J., Mangu P.B., Somerfield M.R., Schrag D., Samson D., Holt L., Zelman D., Ajani J.A. American society of clinical oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 2011, 29:3328-3330.
7. Carlson R.W., Allred D.C., Anderson B.O., Burstein H.J., Carter W.B., Edge S.B., Erban J.K., Farrar W.B., Forero A., Giordano S.H., Goldstein L.J., Gradishar W.J., Hayes D.F., Hudis C.A., Ljung B.M., Mankoff D.A., Marcom P.K., Mayer I.A., McCormick B., Pierce L.J., Reed E.C., Sachdev J., Smith M.L., Somlo G., Ward J.H., Wolff A.C., Zellars R. Invasive breast cancer. J. Natl. Compr. Canc. Netw. 2011, 9:136-222.
8. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., Reuben J.M., Doyle G.V., Allard W.J., Terstappen L.W., Hayes D.F. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
9. Domchek S.M., Friebel T.M., Singer C.F., Evans D.G., Lynch H.T., Isaacs C., Garber J.E., Neuhausen S.L., Matloff E., Eeles R., Pichert G., Van t'veer L., Tung N., Weitzel J.N., Couch F.J., Rubinstein W.S., Ganz P.A., Daly M.B., Olopade O.I., Tomlinson G., Schildkraut J., Blum J.L., Rebbeck T.R. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304:967-975.
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
11. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1995, 56:265-271.
12. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998, 90:1371-1388.
13. Freidlin B., McShane L.M., Korn E.L. Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst. 2010, 102:152-160.
14. Gilligan T.D., Seidenfeld J., Basch E.M., Einhorn L.H., Fancher T., Smith D.C., Stephenson A.J., Vaughn D.J., Cosby R., Hayes D.F. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J. Clin. Oncol. 2010, 28:3388-3404.
15. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250:1684-1689.
16. Hammond M.E., Hayes D.F., Dowsett M., Allred D.C., Hagerty K.L., Badve S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 2010.
17. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., Somerfield M.R., Hayes D.F., Bast R.C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25:5287-5312.
18. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., Locker G.Y., Macdonald J.S., Mennel R.G., Norton L., Ravdin P., Taube S., Winn R.J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 1996, 88:1456-1466.
19. Innocenti F., Ratain M.J. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006, 7:1211-1221.
20. Ioannidis J.P., Panagiotou O.A. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011, 305:2200-2210.
21. Kauff N.D., Satagopan J.M., Robson M.E., Scheuer L., Hensley M., Hudis C.A., Ellis N.A., Boyd J., Borgen P.I., Barakat R.R., Norton L., Castiel M., Nafa K., Offit K. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2002, 346:1609-1615.
22. Khatcheressian J.L., Wolff A.C., Smith T.J., Grunfeld E., Muss H.B., Vogel V.G., Halberg F., Somerfield M.R., Davidson N.E. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol. 2006, 24:5091-5097.
23. Lin K., Lipsitz R., Miller T., Janakiraman S. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2008, 149:192-199.
24. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24:5313-5327.
25. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 2005, 93:387-391.
26. Moore H.M., Kelly A.B., Jewell S.D., McShane L.M., Clark D.P., Greenspan R., Hayes D.F., Hainaut P., Kim P., Mansfield E., Potapova O., Riegman P., Rubinstein Y., Seijo E., Somiari S., Watson P., Weier H.U., Zhu C., Vaught J. Biospecimen reporting for improved study quality (BRISQ). J. Proteome Res. 2011, 10:3429-3438.
27. National Cancer Institute, (accessed on 27.9.11.). http://www.cancer.gov/dictionary%3fCdrID=45618.
28. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
29. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
30. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1659-1672.
31. Ransohoff D.F. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 2007, 60:1205-1219.
32. Ransohoff D.F., Gourlay M.L. Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 2010, 28:698-704.
33. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E., Olopade O.I., Weber B.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002, 346:1616-1622.
34. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
35. Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C., Kristensen G., Mediola C., Coens C., Qian W., Parmar M.K., Swart A.M. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010, 376:1155-1163.
36. Sargent D.J., Conley B.A., Allegra C., Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 2005, 23:2020-2027.
37. Simon R.M., Paik S., Hayes D.F. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009, 101:1446-1452.
38. Taylor C.F., Paton N.W., Lilley K.S., Binz P.A., Julian R.K., Jones A.R., Zhu W., Apweiler R., Aebersold R., Deutsch E.W., Dunn M.J., Heck A.J., Leitner A., Macht M., Mann M., Martens L., Neubert T.A., Patterson S.D., Ping P., Seymour S.L., Souda P., Tsugita A., Vandekerckhove J., Vondriska T.M., Whitelegge J.P., Wilkins M.R., Xenarios I., Yates J.R., Hermjakob H. The minimum information about a proteomics experiment (MIAPE). Nat. Biotechnol. 2007, 25:887-893.
39. Teutsch S.M., Bradley L.A., Palomaki G.E., Haddow J.E., Piper M., Calonge N., Dotson W.D., Douglas M.P., Berg A.O. The evaluation of Genomic applications in practice and prevention (EGAPP) Initiative: methods of the EGAPP Working group. Genet. Med. 2009, 11:3-14.
40. van't Veer L.J., Paik S., Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol. 2005, 23:1631-1635.
41. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., Fleisher M., Lilja H., Brogi E., Boyd J., Sanchez-Carbayo M., Holland E.C., Cordon-Cardo C., Scher H.I., Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 2006, 116:271-284.
42. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.